Recent blog posts
Postpartum depression Indication Strategy Report 2026: GABRA1, Trials and Deals
Latest Hotspot
8 min read
Postpartum depression Indication Strategy Report 2026: GABRA1, Trials and Deals
21 July 2026
Postpartum depression indication strategy report covering epidemiology, GABRA1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Preterm birth Indication Strategy Report 2026: OXTR, Trials and Deals
Latest Hotspot
8 min read
Preterm birth Indication Strategy Report 2026: OXTR, Trials and Deals
21 July 2026
Preterm birth indication strategy report covering epidemiology, OXTR biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Preeclampsia Indication Strategy Report 2026: VEGFR1, Trials and Deals
Latest Hotspot
8 min read
Preeclampsia Indication Strategy Report 2026: VEGFR1, Trials and Deals
21 July 2026
Preeclampsia indication strategy report covering epidemiology, VEGFR1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Vasomotor symptoms of menopause Indication Strategy Report 2026: NK3, Trials and Deals
Latest Hotspot
8 min read
Vasomotor symptoms of menopause Indication Strategy Report 2026: NK3, Trials and Deals
21 July 2026
Vasomotor symptoms of menopause indication strategy report covering epidemiology, NK3 biology, active trials, competition and deal signals using PatSnap MCP...
Read →
Polycystic ovary syndrome Indication Strategy Report 2026: AR, Trials and Deals
Latest Hotspot
8 min read
Polycystic ovary syndrome Indication Strategy Report 2026: AR, Trials and Deals
21 July 2026
Polycystic ovary syndrome indication strategy report covering epidemiology, AR biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Uterine fibroids Indication Strategy Report 2026: PGR-AS1, Trials and Deals
Latest Hotspot
8 min read
Uterine fibroids Indication Strategy Report 2026: PGR-AS1, Trials and Deals
21 July 2026
Uterine fibroids indication strategy report covering epidemiology, PGR-AS1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Endometriosis Indication Strategy Report 2026: ERα, Trials and Deals
Latest Hotspot
8 min read
Endometriosis Indication Strategy Report 2026: ERα, Trials and Deals
21 July 2026
Endometriosis indication strategy report covering epidemiology, ERα biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Retinopathy of prematurity Indication Strategy Report 2026: VEGF-A, Trials and Deals
Latest Hotspot
8 min read
Retinopathy of prematurity Indication Strategy Report 2026: VEGF-A, Trials and Deals
21 July 2026
Retinopathy of prematurity indication strategy report covering epidemiology, VEGF-A biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
X-linked retinoschisis Indication Strategy Report 2026: XLRS1, Trials and Whitespace
Latest Hotspot
8 min read
X-linked retinoschisis Indication Strategy Report 2026: XLRS1, Trials and Whitespace
21 July 2026
X-linked retinoschisis indication strategy report covering epidemiology, XLRS1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Dry eye disease Indication Strategy Report 2026: IL1R1, Trials and Deals
Latest Hotspot
8 min read
Dry eye disease Indication Strategy Report 2026: IL1R1, Trials and Deals
21 July 2026
Dry eye disease indication strategy report covering epidemiology, IL1R1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Keratoconus Indication Strategy Report 2026: LOX, Trials and Deals
Latest Hotspot
8 min read
Keratoconus Indication Strategy Report 2026: LOX, Trials and Deals
21 July 2026
Keratoconus indication strategy report covering epidemiology, LOX biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Noninfectious uveitis Indication Strategy Report 2026: TNF, Trials and Deals
Latest Hotspot
8 min read
Noninfectious uveitis Indication Strategy Report 2026: TNF, Trials and Deals
21 July 2026
Noninfectious uveitis indication strategy report covering epidemiology, TNF biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →